Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity.

The women's health opportunity in the US is $2.75 billion on an annual basis, and it's growing at a compounded rate of 16% per year. Looking forward, demographics, the aging of the population, and technological innovations will continue to fuel growth. New technologies promise to cause one particular category in women's health to blossom; the treatment of uterine fibroids. According to "Women's Health: US Markets for Benign Uterine Condition Management Products," a report recently published by the Medtech Insight division of Windhover Information Inc., the number of fibroid treatments is expected to increase at a compound annual rate of 21.3%. The report also discusses the markets for the treatment of menorrhagia and endometriosis.

In women's health, Novian offers a micro-invasive alternative to lumpectomy. Mirabilis Medica hopes to introduce a non-invasive in-office procedure for the removal of uterine fibroids. Dyn-Bioshaf believes that diagnostics that pinpoint the particular cause of infertility will ultimately help improve the success rates of the In Vitro Fertilization industry.